Eli Lilly to Invest $6 Billion in New API Manufacturing Facility in Alabama, USA
The new Huntsville, Alabama site will produce small molecule and peptide medicines, including oral GLP-1 orforglipron
Eli Lilly and Company has announced a $6 billion investment in a new active pharmaceutical ingredient (API) manufacturing facility in Huntsville, Alabama. The state-of-the-art site will focus on producing small molecule synthetic and peptide medicines, including Lilly’s first oral, small molecule GLP-1 receptor agonist, orforglipron, which the company expects to submit to global regulatory agencies for obesity approval by the end of this year.
This facility marks the third of four new U.S. manufacturing sites Lilly plans to unveil and will bring 450 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians. Construction is expected to begin in 2026, creating 3,000 construction jobs, with completion projected for 2032.
Strengthening U.S. Supply Chains and Innovation
David A. Ricks, Lilly chair and CEO, said:
“Huntsville’s track record of science and innovation, supported by advanced manufacturing expertise and a skilled workforce, makes Alabama an ideal location for Lilly to expand domestic manufacturing capacity for next‑generation medicines. Today’s investment continues the onshoring of active pharmaceutical ingredient (API) production, strengthening supply chain resilience and reliable access to medicines for patients in the U.S.”
Lilly estimates that for every dollar invested in Huntsville, up to four dollars of additional local economic activity could be generated. Each manufacturing job is expected to create several more positions in related sectors, including supply chain, logistics, and retail.
Alabama Welcomes Lilly’s Largest Investment in State History
Kay Ivey, Governor of Alabama, stated:
“Huntsville and our entire state have a proven legacy of innovation, and there is no better home for Lilly than right here in Alabama. Our roots in the biosciences industry run deep, and Alabama’s contributions to this burgeoning sector continue. We are proud to welcome Lilly’s new U.S. manufacturing facility, which we are thrilled is the largest initial investment in our state’s history. No doubt, Alabamians will help Lilly do things that have never been done before, and we will ensure this great company achieves their mission of improving the health and well-being of people all around the country and globe.”
The Greenbrier South site was chosen from more than 300 applications, benefiting from proximity to the HudsonAlpha Institute for Biotechnology, a hub for workforce training and research. The region also offers ready access to utilities, transportation, favorable zoning, and incentives.
Alabama Senator, Katie Britt:
“Today’s announcement is tremendous news for Huntsville and for our state. Lilly’s $6 billion investment and the creation of thousands of good-paying jobs will strengthen domestic production of lifesaving medicines. This commitment further cements ‘Made in Alabama’ manufacturing as the gold standard and will help usher in a new golden age of American manufacturing, right here in Sweet Home Alabama. This project also underscores President Trump’s leadership in driving major domestic investments to revitalize and unleash American manufacturing dominance and biomedical innovation. I’m proud to be a federal partner as we continue working to provide life-changing opportunities for Alabamians so our world-class workforce can continue to power America’s future.”
Mayor of Huntsville, Alabama, Tommy Battle:
“Lilly’s decision to invest $6 billion in a next-generation pharmaceutical manufacturing facility here in Huntsville is a tremendous vote of confidence in our people and our future. Huntsville has long been a place where innovation thrives and hard, ‘impossible’ things get done. We’re proud to welcome Lilly to our community and excited to help shape the next era of breakthrough medicine.”
AI and Next-Gen Tech to Drive Efficient Production
Lilly plans to incorporate advanced technologies, including machine learning, AI, digitally integrated monitoring systems, and advanced data analytics, to ensure right-first-time execution. Digital automation will be embedded throughout the site to streamline operations and deliver a reliable supply of safe, high-quality medicines.
Edgardo Hernandez, Executive Vice President and President of Lilly Manufacturing Operations, said:
“By establishing this new facility, Lilly is deepening America’s expertise in advanced chemical synthesis and setting new standards for sustainable manufacturing. Our investment not only expands our technical capabilities but also reinforces our commitment to environmental stewardship, leveraging innovative processes to minimize waste and achieve carbon neutrality. Each step forward strengthens our U.S. operations and supports healthier communities for the future.”
Lilly’s Broader Domestic Manufacturing Expansion
Earlier this year, Lilly announced plans to strengthen domestic production across therapeutic areas, with new facilities planned in Texas and Virginia and an expansion at its Puerto Rico site. A fourth U.S. location will be disclosed in the coming weeks.
About Eli Lilly and Company
Lilly is a global medicine company focused on turning science into healing. With nearly 150 years of pioneering discoveries, Lilly develops treatments for diabetes, obesity, Alzheimer’s, immune disorders, and difficult-to-treat cancers. The company is committed to innovative clinical trials, accessible medicines, and improving lives worldwide.
Learn more at Lilly.com
Lead Image Credits: Eli Lilly and Company
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-build-6-billion-facility-to-manufacture-active-pharmaceutical-ingredients-in-alabama-302635568.html
Recommended Companies
Latest Projects
- Eli Lilly to Invest $6 Billion in New API Manufacturing Facility in Alabama, USA
The new Huntsville, Alabama site will produce small molecule and peptide medicines, including oral GLP-1 orforglipron Eli Lilly and Company - Eli Lilly’s Next-gen $6.5B API and GLP-1 Orforglipron Facility, Houston, Texas, USA
Eli Lilly and Company has announced plans to build a $6.5 billion next-generation active pharmaceutical ingredient (API) manufacturing facility at - AstraZeneca Unveils $300 Million Cell Therapy Manufacturing Facility in Rockville, USA
Global biopharmaceutical leader AstraZeneca has officially opened a new $300 million state-of-the-art cell therapy manufacturing facility in Rockville, Maryland, marking - Roche to Invest $50B in US Pharma Expansion Set To Flip Trade Deficit
In a transformative move for the U.S. healthcare manufacturing sector, Roche unveiled plans to invest $50 billion in American pharmaceutical - MSD Acquires WuXi Vaccines Facility in Dundalk for €500m
In a significant acquisition move, pharmaceutical giant MSD has agreed to acquire the WuXi Vaccines manufacturing facility in Dundalk, Ireland. - Infrareal to Take Over Takeda’s Gene and Cell Therapy Site in Orth, Austria
Infrareal Holding plans to take over Takeda’s pharma and biotech site specialising in gene and cell therapies in Orth, Lower
More Headlines
